GILD - Gilead Sciences, Inc.
About Gilead Sciences, Inc. (https://www.gilead.com)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Daniel O'Day | Chairman & Chief Executive Officer | 1965 | $8,698,736 USD |
| Dietmar Berger | Chief Medical Officer | 1969 | $5,923,077 USD |
| Johanna Mercier | Chief Commercial & Corporate Affairs Officer | 1970 | $3,436,150 USD |
| Andrew D. Dickinson | Executive VP & CFO | 1970 | $3,143,899 USD |
| Bernard Fine | Vice President of Oncology & Franchise Head of Early Development | – | – |
| Bilal Piperdi | Vice President of Clinical Research Oncology | – | – |
| Erin Burkhart | Senior VP, Controller & Chief Accounting Officer | 1979 | – |
| Flavius Martin | Executive Vice President of Research | – | – |
| Jackson Egen | Vice President of Research Oncology | – | – |
| Jacquie Ross | Senior Vice President of Treasury and Investor Relations | – | – |
| Janet Dorling | Senior Vice President of Intercontinental Region & Global Patient Solutions | 1975 | – |
| Jyoti K. Mehra | Executive Vice President of Human Resources | 1977 | – |
| Keeley Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary | 1975 | – |
| Linda Slanec Higgins | Senior Vice President of Research, Innovation & Portfolio | 1962 | – |
| See-Chun Phan | Vice President of Clinical Research Oncology | 1964 | – |
| Stacey Y. Ma | Executive Vice President of Pharmaceutical Development & Manufacturing | 1971 | – |